UBX Unity Biotechnology

CORRECTING and REPLACING -- UNITY Biotechnology, Inc. to Announce Fourth Quarter and Full Year 2018 Financial Results

CORRECTING and REPLACING -- UNITY Biotechnology, Inc. to Announce Fourth Quarter and Full Year 2018 Financial Results

SAN FRANCISCO, Feb. 27, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline on February 25th by UNITY Biotechnology, Inc. [Nasdaq: UBX], please note that in the first paragraph of the release, financial results will be reported before Nasdaq market open, not after market close. The corrected release follows:

UNITY Biotechnology, Inc. to Announce Fourth Quarter and Full Year 2018 Financial Results

UNITY Biotechnology, Inc. (UNITY) [Nasdaq: UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, plans to report financial results for the fourth quarter and full year ended December 31, 2018, on Wednesday, March 6, 2019, before Nasdaq market open.

UNITY will not conduct a conference call in conjunction with the financial results press release.

About UNITY

UNITY Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. More information is available at or follow us on .

Media
Austine Graff
UNITY Biotechnology
707-593-6151
EN
27/02/2019

Underlying

UBXUnity Biotechnology

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Unity Biotechnology

 PRESS RELEASE
Free
UBX Unity Biotechno...

UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE...

UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population  UBX1325 generally outperformed aflibercept in a pre-specified subgroup of patients entering the study with CST

May 5, 2025 1 EN
 PRESS RELEASE
Free
UBX Unity Biotechno...

UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting

UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the Company will present 36-week data from the ASPIRE Phase 2B study at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting being held on May 4-8, 2025 in Salt Lake City, Utah. ARVO 2025 Presentation Details: Title: Safety and Efficacy of Senolytic Candidate UBX1325 for D...

May 1, 2025 1 EN
 PRESS RELEASE
Free
UBX Unity Biotechno...

UNITY Biotechnology Announces Publication in NEJM Evidence Highlightin...

UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the peer-reviewed journal results from the Phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME). As reported in the article titled, “Safety and Efficacy of Senolytic UBX1325 in D...

April 23, 2025 1 EN
 PRESS RELEASE
Free
UBX Unity Biotechno...

UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results...

UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2025. UNITY announced 24-week and partial 36-week topline data from our Phase 2b ASPIRE study in diabetic macular edema (DME) in the first quarter. DME patients treated with UBX1325 (foselutoclax) showed vision improvements ...

April 22, 2025 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
TTSH Tile Shop Holdi...
PBF PBF Energy Inc... ... (+19)

InsiderInsights.com Daily Ratings Report: April 3, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

TTSH TILE SHOP HOLDINGS INC.
PBF PBF ENERGY INC. CLASS A
CVGW CALAVO GROWERS INC.
CRMD CORMEDIX INC.
CDXS CODEXIS
WGO WINNEBAGO INDUSTRIES INC.
UBX UNITY BIOTECHNOLOGY
FGBI FIRST GUARANTY BANCSHARES
PCB PACIFIC CITY FINANCIAL CORP
APA APA CORPORATION
NUVB NUVATION BIO INC (A)
FTCI FTC SOLAR
BTMD INC.
TEAF HAYMAKER ACQUISITION CORP III
BTM ECOFIN SUSTAINABLE AND SOCIAL IMPACT TERM FUND
STSFF BITCOIN DEPOT INC
ECF SMARTSTOP SELF STORAGE REIT
INC.
ELLSWORTH FUND LTD
04/04/25 April 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch